• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up1.23% Nasdaq Up1.74%

    Impax Laboratories Inc. (IPXL)

    38.20 Up 1.91(5.26%) Oct 2, 4:00PM EDT
    ProfileGet Profile for:
    Impax Laboratories Inc.
    30831 Huntwood Avenue
    Hayward, CA 94544
    United States - Map
    Phone: 510-476-2000
    Fax: 510-240-6096
    Website: http://www.impaxlabs.com

    Index Membership:N/A
    Industry:Drug Manufacturers - Major
    Full Time Employees:1,061

    Business Summary 

    Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products. It operates in two segments, Global Pharmaceuticals Division and Impax Pharmaceuticals Division. The Global Pharmaceuticals Division provides generic pharmaceutical products through its global products sales channel directly to wholesalers, large retail drug chains, and others; generic prescription products through third-party pharmaceutical entities to alliance and collaboration agreements; generic pharmaceutical over-the-counter (OTC) and prescription products to third parties; and generic pharmaceutical OTC products through third-party pharmaceutical companies. The Impax Pharmaceutical Division focuses on the development and promotion through its specialty sales force of proprietary brand pharmaceutical products for the treatment of central nervous system disorders, including migraine, multiple sclerosis, Parkinson’s disease, and postherpetic neuralgia. The company markets and sells its products to drug wholesalers, warehousing chain drug stores, mass merchandisers, and mail-order pharmacies in the continental United States and the Commonwealth of Puerto Rico. Impax Laboratories, Inc. has a strategic alliance agreement with Teva Pharmaceuticals Curacao N.V to develop, manufacture, and distribute controlled release generic pharmaceutical products. The company was founded in 1993 and is headquartered in Hayward, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Impax Laboratories Inc.

    Corporate Governance 
    Impax Laboratories Inc.’s ISS Governance QuickScore as of Oct 1, 2015 is 6. The pillar scores are Audit: 10; Board: 7; Shareholder Rights: 2; Compensation: 9.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. George Frederick Wilkinson , 59
    Chief Exec. Officer, Pres and Director
    Mr. Bryan M. Reasons , 48
    Chief Financial Officer and Sr. VP of Fin.
    Mr. Jeffrey D. Nornhold , 49
    Sr. VP of Technical Operations
    Mr. Mark A. Schlossberg Esq., 54
    Sr. VP, Gen. Counsel and Sec.
    Mr. Michael J. Nestor , 61
    Pres of Impax Pharmaceuticals
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders